Abstract
Objective: To determine the potential effectiveness and toxicity of this therapy in children with advanced neuroblastoma or malignant lymphoma. Methods: Carboplatin (425 mg/m2·d) and etoposide (338 mg/m2·d) were given as a 24 h continuous IV infusion on days -7, -6, -5 and -4, and melphalam (70 mg/m2·d) by bolus IV infusion at hour 0 of days -7, -6, and-5(CEM). Or busulphan was given as 1 mg/kg·6 h orally on days -6, -5, -4, and melphalam (140 mg/m2) by IV bolus infusion on day — 3(BM). Treatment regimens followed by autologous PBSC infusion were performed in 19 children with neuroblastoma (n=12) or malignant lymphoma (n=7) for consolidation treatment. There were thirteen males and six females, with a median age of 6.4 years (raging 3.5∼13 years). Results: The median period of achieving ANC >0.5×109/L, WBC>1.0×109/L, and platelet >20×109/L after infusion of PBSCs were 21 d, 17 d, and 33 d respectively. Stomatitis occurred in 16 children (86%), and twelve had gastrointestinal toxicity (64%). Complete remission (CR) was achieved in 14 (74%) children. Fifteen patients (79%) survived. Ten patients (53%) are alive in CR. These patients are alive for a median of 639 days and disease-free for 909 d after transplantation. Four cases (21%) relapsed, and four cases (21%) died. Conclusion: CEM or BM regimen followed by autologous PBSCT infusion is safe and feasible, and has significant effects in children with advanced neuroblastoma or malignant lymphoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schiffman KS, Bensiger WI, Appelbaum FR, et al. Phase II study of high-dose busukfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease[J]. Bone Marrow Transplant 1996; 17: 943–50.
Brice P, Marolleau JP, Dombret H, et al. Autologous peripheral blood stem cell transplantaqtion after high dose therapy in patients with advanced lymphomas[J]. Bone Marrow Transplant 1992; 9: 337–42.
Lü SG, Peng YY, Tang SQ, et al. Analysis of the therapeutic effects of autologous peripheral blood stem cell transplantation on malignant tumor in children[J]. Chin J Pediatr 1997; 35:233–5.
Prodeur GM, Hayes FA, Green AA, et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients[J]. Cancer Res 1987; 47: 4248–53.
Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastoma tumor: definition of subtypes of ganglioheuroblastoma and an age-linked classification of neuroblastoma[J]. J Natl Cancer Inst 1984; 73: 405–16.
Matthay KK, O’Leary MC, Ramsay NK, et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children Cancer Group results[J]. Eur J Cancer 1995; 31: 572–5.
Sun XF, Su YS, Liu DG. Comparing CHOP, CHOP+HE-MTX, and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin’s lymphoma[J]. Chin J Cancer 2004; 23: 933–8.
Sanders JE, The Seattle Marrow Transplant Team. The impact of marrow transplant preparative regimen on subsequent growth and development[J]. Seminars in Hematol 1991; 28: 244–9.
Sanders JE, the Seattle Marrow Transplant Team. Late effects in children receiving total body irradiation for bone marrow transplantation[J]. Radiother Oncol 1990; 18(Supp 1): 82–7.
Author information
Authors and Affiliations
Corresponding author
Additional information
Biography: WANG Jian-wen(1965–), male, master of medicine, associated professor, Department of Pediatrics, General Hospital of PLA, majors in hematology and oncology of pediatric.
Rights and permissions
About this article
Cite this article
Wang, Jw., Tang, Sq., Yang, G. et al. High-dose chemotherapy with autologous peripheral blood stem cell support in children with malignant diseases. Chin. J. Cancer Res. 17, 288–290 (2005). https://doi.org/10.1007/s11670-005-0028-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11670-005-0028-z